

# Francesca Maria Rossi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1647388/publications.pdf>

Version: 2024-02-01

93  
papers

3,166  
citations

186265

28  
h-index

168389

53  
g-index

94  
all docs

94  
docs citations

94  
times ranked

3864  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1403-1412.	1.4	420
2	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 865-873.	1.4	226
3	Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2008, 142, 202-215.	2.5	206
4	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. <i>Cancer Research</i> , 2009, 69, 4001-4009.	0.9	153
5	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4902-4905.	1.4	113
6	CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin. <i>Blood</i> , 1997, 89, 2048-2059.	1.4	110
7	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	2.5	106
8	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129.	7.0	92
9	Hyaluronan-CD44 interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. <i>Journal of Cell Biology</i> , 2002, 158, 1133-1144.	5.2	83
10	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. <i>Leukemia</i> , 2016, 30, 182-189.	7.2	74
11	CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. <i>Haematologica</i> , 2008, 93, 1575-1579.	3.5	72
12	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643.	2.8	67
13	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 681-697.	8.5	65
14	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	3.5	64
15	Expression of Functional Interleukin-3 Receptors on Hodgkin and Reed-Sternberg Cells. <i>American Journal of Pathology</i> , 2002, 160, 585-596.	3.8	56
16	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, 77-85.	3.5	53
17	NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. <i>Leukemia</i> , 2017, 31, 2407-2415.	7.2	52
18	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , 2013, 122, 3317-3321.	1.4	48

#	ARTICLE	IF	CITATIONS
19	<i>SMARCB1</i> / <i>INI1</i> Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1060-1072.	4.1	46
20	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628.	7.0	44
21	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. <i>Leukemia</i> , 2016, 30, 2011-2018.	7.2	41
22	ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 284-292.	1.5	38
23	Practical Method for the Multigram Separation of the 5- and 6-Isomers of Carboxyfluorescein. <i>Bioconjugate Chemistry</i> , 1997, 8, 495-497.	3.6	37
24	Improved GMP compliant approach to manipulate lipoaspirates, to cryopreserve stromal vascular fraction, and to expand adipose stem cells in xeno-free media. <i>Stem Cell Research and Therapy</i> , 2018, 9, 130.	5.5	36
25	In vitro studies on the potential use of 5-aminolaevulinic acid-mediated photodynamic therapy for gynaecological tumours. <i>British Journal of Cancer</i> , 1996, 74, 881-887.	6.4	34
26	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , 2014, 93, 1765-1774.	1.8	34
27	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	1.4	33
28	CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. <i>Haematologica</i> , 2012, 97, 279-287.	3.5	32
29	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: The Master Role of CD49d. <i>Seminars in Hematology</i> , 2014, 51, 168-176.	3.4	32
30	NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF- $\kappa$ B pathways. <i>Leukemia</i> , 2018, 32, 654-662.	7.2	31
31	Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance. <i>Blood</i> , 2014, 124, 3831-3833.	1.4	27
32	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. <i>British Journal of Haematology</i> , 2004, 125, 203-212.	2.5	26
33	Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , 2013, 31, 88-95.	1.7	25
34	Long term cryopreservation in 5% <i>DMSO</i> maintains unchanged <i>CD</i> <sup>34</sup> cells viability and allows satisfactory hematological engraftment after peripheral blood stem cell transplantation. <i>Vox Sanguinis</i> , 2013, 105, 77-80.	1.5	23
35	<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.	7.0	23
36	Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. <i>British Journal of Haematology</i> , 1999, 104, 152-162.	2.5	22

#	ARTICLE	IF	CITATIONS
37	<i><sc>NOTCH</sc>1</i> mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018, 182, 597-602.	2.5	22
38	Frequent Expression of the Variant CD30 in Human Malignant Myeloid and Lymphoid Neoplasms. <i>American Journal of Pathology</i> , 1999, 155, 2029-2041.	3.8	21
39	Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait. <i>British Journal of Haematology</i> , 2008, 141, 734-736.	2.5	21
40	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019, 33, 2111-2115.	7.2	21
41	CD30L up-regulates CD30 and IL-4 expression by T cells. <i>FEBS Letters</i> , 2001, 508, 418-422.	2.8	20
42	Hodgkin's disease: A disorder of dysregulated cellular cross-talk. <i>Biotherapy (Dordrecht, Tj ETQq0 0 0 rgBT /Overlock 10 Jf 50 542 T</i>	0.7	19
43	The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation. <i>British Journal of Haematology</i> , 1999, 105, 225-240.	2.5	19
44	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. <i>Journal of Translational Medicine</i> , 2010, 8, 23.	4.4	19
45	Normalizing Complementary DNA by Quantitative Reverse Transcriptase-Polymerase Chain Reaction of Î²2-Microglobulin: Molecular Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia. <i>Diagnostic Molecular Pathology</i> , 2000, 9, 98-109.	2.1	19
46	Mutations in the 3' untranslated region of <i>NOTCH1</i> are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e305-e309.	3.5	18
47	Cluster analysis of immunophenotypic data: The example of chronic lymphocytic leukemia. <i>Immunology Letters</i> , 2011, 134, 137-144.	2.5	17
48	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	7.2	17
49	COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2021, 39, 712-714.	1.7	17
50	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 95-106.	1.3	16
51	Competitive reverse-transcriptase PCR: a useful alternative to Northern blotting for quantitative estimation of relative abundances of specific mRNAs in precious samples. <i>Biochemical Journal</i> , 1997, 325, 565-567.	3.7	15
52	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	3.5	15
53	Clinical significance of c.7544-7545 del<sc>CT</sc><i><sc>NOTCH</sc>1</i> mutation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 415-418.	2.5	14
54	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013, 6, 83.	17.0	14

#	ARTICLE	IF	CITATIONS
55	A new freezing and storage procedure improves safety and viability of haematopoietic stem cells and neutrophil engraftment: a single institution experience. <i>Vox Sanguinis</i> , 2010, 98, 172-180.	1.5	13
56	Differential expression of the RET gene in human acute myeloid leukemia. <i>Annals of Hematology</i> , 1998, 77, 207-210.	1.8	12
57	Clinical Impact of Clonal and Subclonal TP53 Mutations and Deletions in Chronic Lymphocytic Leukemia: An Italian Multicenter Experience. <i>Blood</i> , 2019, 134, 480-480.	1.4	12
58	&lt;i&gt;SF3B1&lt;/i&gt;-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. <i>Haematologica</i> , 2021, 106, 3125-3135.	3.5	12
59	CD30 Ligand (CD30L)-Expressing Acute Myeloid Leukemias: A New Model of Paracrine Interactions for the Regulation of Blast Cells Proliferation. <i>Leukemia and Lymphoma</i> , 1999, 35, 21-35.	1.3	11
60	Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e443-e446.	3.5	11
61	Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia. <i>Current Cancer Drug Targets</i> , 2016, 16, 659-668.	1.6	11
62	Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells. <i>British Journal of Haematology</i> , 2002, 117, 59-69.	2.5	10
63	Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome. <i>American Journal of Hematology</i> , 2010, 85, 619-622.	4.1	10
64	CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34+ hemopoietic progenitors cells. <i>Leukemia</i> , 2014, 28, 705-708.	7.2	10
65	Assessment of the 4&Ecirc;factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	4.1	10
66	Biallelic <i>BIRC3</i> inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. <i>British Journal of Haematology</i> , 2019, 185, 156-159.	2.5	9
67	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. <i>Haematologica</i> , 2021, 106, 2345-2353.	3.5	8
68	<sc><i>TP53</i></sc> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	4.1	8
69	Flow Cytometric Technique for Quantitating Cytotoxic Response to Photodynamic Therapy. <i>Photochemistry and Photobiology</i> , 1996, 63, 111-116.	2.5	7
70	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib&Ecirc;rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	6.2	7
71	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. <i>Haematologica</i> , 2019, 104, e410-e414.	3.5	5
72	Comparison of ibrutinib and idelalisib plus rituximab in real&Ecirc;life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	2.2	5

#	ARTICLE	IF	CITATIONS
73	NOTCH1 Mutations Are Associated with Low CD20 Expression in Chronic Lymphocytic Leukemia: Evidences for a NOTCH1-Mediated Epigenetic Regulatory Mechanism. <i>Blood</i> , 2014, 124, 296-296.	1.4	5
74	Photosensitizing activity of water- and lipid-soluble phthalocyanines on <i>Escherichia coli</i> . <i>FEMS Microbiology Letters</i> , 1990, 71, 149-156.	1.8	4
75	<i>PDCD1</i> and <i>IFNL4</i> genetic variants and risk of developing hepatitis C virusâ€related diseases. <i>Liver International</i> , 2021, 41, 133-149.	3.9	3
76	Effectiveness of ibrutinib as firstâ€line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximabâ€bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	4.1	3
77	The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4397-4397.	1.4	3
78	Elastin Microfibril Interfacer1 (EMILINâ€1) is an alternative prosurvival VLAâ€4 ligand in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2022, 40, 181-190.	1.7	3
79	Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4396-4396.	1.4	2
80	INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE. <i>Hematological Oncology</i> , 2017, 35, 109-110.	1.7	1
81	CD49d Is Overexpressed in Trisomy 12 Chronic Lymphocytic Leukemia by an Epigenetic-Dependent Transcriptional Control. <i>Blood</i> , 2012, 120, 929-929.	1.4	1
82	Bendamustine Improves Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) According to Different Clinical and Biological Prognostic Factors. <i>Blood</i> , 2014, 124, 5668-5668.	1.4	1
83	Molecular, Phenotypic and Clinical Predictors of Richter Syndrome (RS) in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2007, 110, 3086-3086.	1.4	1
84	THU0299â€...B Cell Compartment and Pharmacodynamics of Belimumab in Systemic Lupus Erythematosus: Early Clinical Efficacy by Depletion of CD27- and Increase of CD27+ B Cells: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 295.1-295.	0.9	0
85	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3578-3578.	1.4	0
86	Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 2692-2692.	1.4	0
87	Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2870-2870.	1.4	0
88	Clinical Significance of 13q14 Number of Deleted Cells in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 4581-4581.	1.4	0
89	Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 712-712.	1.4	0
90	NOTCH1 Mutations Are Associated with High CD49d Expression in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 1978-1978.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Intraclonal Diversification Occurs in Chronic Lymphocytic Leukemia Expressing B Cell Receptors Belonging to the IGHV4 Gene Family. <i>Blood</i> , 2018, 132, 944-944.	1.4	0
92	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. <i>Blood</i> , 2018, 132, 4399-4399.	1.4	0
93	The VLA-4 Integrin Is Constitutively Activated in a Fraction of CD49d-Expressing Chronic Lymphocytic Leukemia Via Autonomous BCR-Mediated Signaling. <i>Blood</i> , 2019, 134, 849-849.	1.4	0